NorthWest Biotherapeutics Inc (NWBO)

[photonic5]

The booths at ASCO this year should really focus on marketing to right to try patients. With RTT becoming the law any day now, NWBO should be able to provide information on how to obtain DCVax L for recurrent patients through RTT. That alone will begin to generate revenue for the company. Once topline is released, they can get through approval and start negotiating reimbursement with insurances. That funds further trials, new indications, etc.

The biggest question in my mind is whether BP lets it get that far. A 5-10 billion dollar buyout probably accompanies topline data that meets endpoints.